May 01, 2019 / 12:00PM GMT
Operator
Good day, ladies and gentlemen. Welcome to the Nabriva Therapeutics Conference Call. (Operator Instructions) As a reminder, this call is being recorded.
I would now like to introduce your host for today's conference, David Garrett, Vice President, Corporate Controller and Head of Investor Relations. Please go ahead.
David Garrett - Nabriva Therapeutics AG - Head of IR, VP & Corporate Controller
Thank you, and good morning, everyone. Welcome to Nabriva's conference call to discuss the Complete Response Letter from the FDA for CONTEPO. A press release summarizing the Complete Response Letter was issued yesterday and can be found at www.nabriva.com.
Before we begin, I'd like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of the date of
Nabriva Therapeutics plc Complete Response Letter from FDA on NDA Conference Call Transcript
May 01, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers